How Will the Chronic Liver Diseases Therapeutics Market Grow? Key Trends and Opportunities for 2025 and Beyond
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Will the Chronic Liver Diseases Therapeutics Market Grow Over the Forecast Period Based on Its Expected CAGR?
The market size for therapeutics of chronic liver disease has seen a swift expansion in the past few years. It is projected to escalate from $14.38 billion in 2024 to $15.92 billion in 2025, showcasing a compound annual growth rate (CAGR) of 10.7%. Factors such as heightened instances of viral hepatitis, rising obesity rates, an aging populace, growing cognizance of liver health, and wider patient access to appropriate treatments have contributed to this growth rate during the historical period.
The projected expansion for the chronic liver disease therapeutics market is predicted to balloon at a significant pace in the upcoming years, pushing its worth to $23.83 billion in 2029 and posting a compound annual growth rate (CAGR) of 10.6%. The uplift in forecast is attributed to several elements – enhanced adoption of personalized medicine, the development of new, innovative treatments, an increase in telemedicine and digital health solutions, and the heightened need for liver disease prevention schemes, alongside the surging cases of viral hepatitis. Key trends emerging in the market include the integration of AI in diagnosis, the use of biologics and gene therapies, non-invasive treatments, combined therapies, and the broadening of patient-focused care models.
What Factors Are Propelling the Growth of the Chronic Liver Diseases Therapeutics Market from 2025 to 2034?
The chronic liver disease therapeutics market’s growth is anticipated to be driven by the rise in alcohol consumption. Ethanol-containing beverages, also known as alcohol, is consumed in varying degrees, from moderate to excessive, which can potentially affect health. The escalation in drinking alcohol can be attributed to its growing social acceptance, surging incomes, and increased availability across the globe. Therapeutics for chronic liver disease are used to control liver damage resulting from high alcohol consumption, slowing the progression of the disease and enhancing liver function. For example, the First Citizens Bank, a US-based financial institution, reported in June 2024 that a 1.2% surge in direct-to-consumer (DTC) wine case sales occurred in 2023 compared to 2022. Furthermore, the Kirin Holdings Company Limited, a beverage company based in Japan, published a report in December 2023 indicating that approximately 192.1 million kiloliters of beer were consumed in 2022, marking a 2.9% rise from the previous year. Consequently, the upsurge in alcohol consumption is fueling the expansion of the chronic liver disease therapeutics market.
Get Your Free Sample of the Global Chronic Liver Diseases Therapeutics Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21145&type=smp
Who Are the Dominant Players Expanding Their Reach in the Chronic Liver Diseases Therapeutics Market?
Major companies operating in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy’s Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.
What Are the Top Trends Shaping the Evolution of the Chronic Liver Diseases Therapeutics Market?
Leading enterprises in the chronic liver diseases therapeutics market are concentrating on the development of innovative solutions, such as RNA therapies, which target fundamental genetic and molecular mechanisms, thereby providing more efficient and personalized treatment options. RNA therapies employ RNA molecules to control gene expression or protein synthesis with an objective to prevent or treat diseases by targeting unique genetic mechanisms. For instance, in May 2022, Ochre Bio, a biotechnological firm based in the UK, introduced its revolutionary research facility called ‘Liver ICU’ at BioLabs@NYULangone, a biopharmaceutical incubator located in New York City. This advanced site evaluates the effectiveness of next-generation RNA therapeutics by using entire human livers maintained on perfusion machines. The facility aims to expedite the drug development process and enhance the accuracy of liver treatment studies by mimicking human physiological conditions, utilizing discarded donor livers for research.
Get Instant Access to the Global Chronic Liver Diseases Therapeutics Market Report with Swift Delivery!
Which Market Segments Are Driving Strategic Growth and Trends in the Chronic Liver Diseases Therapeutics Market?
The chronic liver diseases therapeutics market covered in this report is segmented –
1) By Treatment Type: Antiviral Drugs, Immunosuppressants Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy
2) By Disease Type: Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders
3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues, Interferons, Direct-Acting Antivirals
2) By Immunosuppressants: Calcineurin Inhibitors, mTOR Inhibitors, Purine Synthesis Inhibitors
3) By Vaccines: Hepatitis A Vaccine, Hepatitis B Vaccine, Combination Hepatitis Vaccines
4) By Immunoglobulins: Hepatitis B Immune Globulin, Intravenous Immunoglobulin
5) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone
6) By Targeted Therapy: Tyrosine Kinase Inhibitors, Monoclonal Antibodies
7) By Chemotherapy: Systemic Chemotherapy, Transarterial Chemoembolization Agents
Which Regions Are Setting the Pace for Chronic Liver Diseases Therapeutics Market Growth?
North America was the largest region in the chronic liver diseases therapeutics market in 2024. The regions covered in the chronic liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Is the Chronic Liver Diseases Therapeutics Market Defined Across Different Regions?
Chronic liver disease therapeutics refers to the medical treatments and interventions aimed at managing long-term liver conditions. These therapies focus on slowing disease progression, alleviating symptoms, and improving liver function through medications, lifestyle changes, and, in some cases, advanced procedures.
Browse Through More Similar Reports By The Business Research Company:
Urothelial Carcinoma Treatment Global Market Report 2025
Mineral And Bone Disorder Treatment Global Market Report 2025
Pancreatic Cancer Drugs Global Market Report 2025
https://thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
